5930112 Health, Department of - Notice of Emergency Rulemaking - Amendments to Schedules I and IV, Controlled Substances
-
DEPARTMENT OF HEALTH
NOTICE OF EMERGENCY RULEMAKING
The Director of the Department of Health, pursuant to the authority set forth in § 201(a) of the District of Columbia Uniform Controlled Substances Act of 1981, effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code § 48-902.01(a) (2014 Repl. & 2015 Supp.)) and Mayor's Order 98-49, dated April 15, 1998, hereby gives notice of the adoption, on an emergency basis, of the following amendments to Chapter 12 (Controlled Substances Act Rules) of Title 22 (Health), Subtitle B (Public Health and Medicine) of the District of Columbia Municipal Regulations (DCMR).
The emergency rules update the list of Schedule I and Schedule IV drugs.
Emergency action is necessary because the updated list includes cannabimimetic drugs that have no legitimate medical use, are readily available, and pose an immediate risk to public health and safety because of their harmful effects when abused. The public health threats from using these drugs include vomiting, anxiety, agitation, irritability, seizures, hallucinations, tachycardia, elevated blood pressure, and loss of consciousness.
These emergency rules were adopted on February 22, 2016, became effective immediately, and shall expire on June 21, 2016, unless superseded by publication of another rulemaking notice in the D.C. Register.
Chapter 12, CONTROLLED SUBSTANCES ACT RULES, of Title 22-B DCMR, PUBLIC HEALTH AND MEDICINE, is amended as follows:
Section 1201, SCHEDULE I ENUMERATED, is amended as follows:
Subsection 1201.1(c) is amended by striking the word “and” at the end of paragraph (45) and adding 40 new paragraphs to be numbered (47) through (86) as follows:
(47) (2C-T) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine; OR 4-methylthio-2,5-dimethoxyphenethylamine;
(48) 4- methylthio-2,5-dimethoxyphenethylamine;
(49) (2C-B-butterFLY) 2-(10-Bromo-2,3,4,7,8,9 hexahydropyrano[2,3-g]chromen-5-yl)ethanamine;
(50) (2C-B-FLY) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4- yl)ethanamine;
(51) (2C-B-hemiFLY, 2CB-5- hemiFLY) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4- yl)ethanamine;
(52) (2C-B-FLY-NBOMe) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-b:4,5-b']difuran-4-yl)-2-aminoethane;
(53) (2C-B-NBOMe, 2,5B-NBOMe) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl) phenethylamine;
(54) 2CBCB-NBOMe N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine;
(55) 2C-C-NBOMe, 2,5C-NBOMe 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; OR 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
(56) 2C-H-NBOMe, 2,5H-NBOMe 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine;
(57) 2C-I-NBOH, 2,5I-NBOH N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine;
(58) 2C-I-NBOMe, 2,5INBOMe, 2,5I-NBOMe, 25I-NBOMe, NBOMe-2C-I, BOM-CI 2- 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; OR 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
(59) (2CBCB-NBOMe) N-(2-methoxybenzyl)-1-[(7R)-3-bromo-2,5- dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methanamine
(60) (2C-H-NBOMe, 2,5H-NBOMe) 2-(2,5-dimethoxyphenyl)-N-[(2-ethoxyphenyl)methyl]ethanamine
(61) (2C-I-NBOH, 2,5I-NBOH) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine;
(62) 2C-TFM-NBOMe) 2-(4-trifluoromethyl-2,5-dimethoxyphenyl)-N-[(2-ethoxyphenyl)methyl]ethanamine;
(63) (25I-NBF) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2- fluorophenyl)methyl]ethanamine;
(64) (25I-NBMD, NBMD-2C-I, Cimbi-29) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2,3ethylenedioxyphenyl)methyl]ethanamine;
(65) (3C-B-FLY) 2-(4-bromo-2,3,6,7-tetrahydrofurobensofuran-8-yl)-1- methyl-ethylamine;
(66) (4-CAB, AEPCA) 4-Chlorophenylisobutylamine; OR 1-(4-chlorophenyl)butan-2-amine; OR 4-chloro-α-ethylphenethylamine;
(67) (4-FA, PAL-303, Flux, Flits, R2D2) para-fluoroamphetamine; OR 4-fluoroamphetamine; OR (RS)-1-(4-Fluorophenyl)propan-2-amine;
(68) (5-APB) 5-(2-Aminopropyl)benzofuran;
(69) (5-APDB) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran;
(70) (6-APB; Benzofury) 6-(2-aminopropyl)benzofuran; OR 1-benzofuran-6-ylpropan-2-amine;
(71) (6-APDB) 6-(2-Aminopropyl)-2,3,-dihydrobenzofuran;
(72) (APB) ((2-aminopropyl)benzofuran); OR [(2- aminopropyl)benzofuran]; OR (2-aminopropyl)benzofuran;
(73) (APDB) ((2-aminopropyl)-2,3-dihydrobenzofuran); OR [(2- aminopropyl)-2,3-dihydrobenzofuran]; OR (2-aminopropyl)- 2,3-dihydrobenzofuran;
(74) (bromo-dragonFLY) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine; OR bromo-benzodifuranyl-isopropylamine;
(75) (DOB) 2,5-Dimethoxy-4-bromoamphetamine; OR 1-(4-Bromo-2,5- dimethoxyphenyl)-2-aminopropane;
(76) (DOC) 2,5-Dimethoxy-4-chloroamphetamine; OR 1-(4-chloro-2,5- dimethoxy-phenyl)propan-2-amine; OR 4-chloro-2,5- dimethoxyamphetamine;
(77) (DOI) 2,5-dimethoxy-4-iodoamphetamine; OR 1-(2,5-dimethoxy-4- iodophenyl)-propan-2-amine; OR 4-iodo-2,5- dimethoxyamphetamine;
(78) DOM, STP 4-methyl-2,5-dimethoxy-amphetamine; OR 4-methyl-2,5-dimethoxy-a-methylphenethylamine;
(79) (Fluoroamphetamine);
(80) MDA 3,4-methylenedioxy amphetamine;
(81) MDMA 3,4-methylenedioxymethamphetamine;
(82) MDE, MDEA3,4-methylenedioxy-N-ethylamphetamine; OR N-ethylalpha-methyl-3,4(methylenedioxy)phenethylamine;
(83) Mescaline 3,4,5-trimethoxyphenethylamine;
(84) (Mescaline-NBOMe) N-(2-Methoxybenzyl)-2-(3,4,5- trimethoxyphenyl)ethanamine; OR 3,4,5-trimethoxy-N-(2- methoxybenzyl)phenethylamine;
(85) (PMMA, 4-MMA) para-Methoxy-N-methylamphetamine; OR 4-methoxy-N- methylamphetamine; OR 1-(4-methoxyphenyl)-N-methyl- propan-2-amine; and
(86) TMA 3,4,5-trimethoxyamphetamine;
Subsection 1201.1(e) is amended to read as follows:
(e) Stimulants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
(1) Alpha-ethyltryptamine;
(2) Alpha- ethyltryptamine;
(3) Aminorex;
(4) Cathinone; Any compound (not being bupropion) structurally derived from 2-amino-1-phenyl-1-propanone by modification in any of the following ways:
(A) By substitution in the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one or more other univalent substituents;
(B) By substitution at the 3-position with an alkyl substituent; or
(C) By substitution at the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure;
(5) 2-diphenylmethylpyrrolidine, including 2-Benzylhydrylpyrrolidin, (S)-(-)-2-(diphenylmethyl)pyrrolidine, (S)-2-diphenylmethylpyrrolidine; (2S)-2-Benzylhydrylpyrrolidine; (2S) diphenylmethylpyrrolidine;
(6) Fenethylline;
(7) Mephedrone (4-methyl-N-ethylcathinone), BZ-6378, 4-methylephedrone;
(8) Methcathinone, including 4-MEC 4-methyl-N-ethylcathinone, 4-methylethcathinone, para-methyl-N-ethylcathinone, para-methylethcathinone, 4-methyl-ethylcathinone;
(9) Methylenedioxypyrovalerone (MDPV);
(10) Methylone;
(11) N-Benzylpiperazine, (BZP) benzylpiperazine, N-benzylpiperazine;
(12) N-ethylamphetamine;
(13) N-Hydroxy-3, 4-methylenedioxyamphetamine;
(14) N, N-Dimethylamphetamine;
(15) 4-methyl-N-ethylcathinone (“4-MEC”);
(16) 4-methyl-alpha-pyrrolidinopropiophenone (“4-MePPP”);
(17) Alpha-pyrrolidinopentiophenone (“α-PVP”), (a-PVP, alpha-PVP), a-Pyrrolidinopentiophenone, 1-phenyl-2-(1 -pyrrolidinyl)-1-pentanone, alpha-pyrrolidinovalerophenone, a-pyrrolidinovalerophenone;
(18) 1-(1, 3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (“butylone”);
(19) 2-(methylamino)-1-phenylpentan-1-one (“pentedrone”);
(20) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (“pentylone”);
(21) 4-fluoro-N-methylcathinone (“4-FMC”), including 4-ethylmethcathinone, 4-ethyl-methcathinone, Flephedrone, 4-fluoromethcathinone;
(22) 3-fluoro-N-methylcathinone (“3-FMC”), 3-fluoromethcathinone;
(23) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (“naphyrone”);
(24) Alpha-pyrrolidinobutiophenone (“α-PBP”) (a-PBP, alpha-PBP) alpha-Pyrrolidinobutiophenone, a-Pyrrolidinobutiophenone, (RS)1-phenyl-2-(1-pyrrolidinyl)-1-pentanone;
(25) 2-DPMP, including desoxypipradrol, diphenylprolinol, 2-
Diphenylmethylpiperidine, 2-benzhydrylpiperidine;
(26) 2-FMC, 2-fluoromethcathinone;
(27) 3,4-DMMC, 3,4-dimethylmethcathinone;
(28) 4-MBC, Benzedrone, (±)-1-(4-methylphenyl)-2-(benzylamino)propan-1-one, 4-methyl-N-benzylcathinone,N-benzyl-4-methylcathinone, 1-(4 methylphenyl)-2-benzyla-minopropan-1-one;
(29) 4-MeMABP, 4-methylbuphedrone, (2-Methylamino-1-(4-methylphenyl)butan-1-one), 2-methylamino-1-(4-methylphenyl)butan-1-one;
(30) a-PPP, alpha-PPP, alpha-pyrrolidinopropiophenone, a-pyrrolidinopropiophenone;
(31) Buphedrone, a-methylamino-butyrophenone, 2-(methylamino)-1-phenylbutan-1-one, alpha-methylamino-butyrophenone;
(32) Butylone, bk-MBDB, beta-Keto-N-methylbenzodioxolylpropylamine, beta-Keto-N-methyl-3,4-benzodioxyolybutanamine;
(33) D2PM, diphenyl-2-pyrrolidinyl-methanol;
(34) Dimethocaine, (3-diethylamino-2,2-dimethylpropyl)-4-aminobenzoate;
(35) DMBDB, bk-DMBDB,dibutylone, 1-(Benzo[d][1,3]dioxol-5-yl)-2-(dimethylamino)butan-1-Dibutylone) one;
(36) DMEC, dimethylethcathinone;
(37) DMMC, dimethylmethcathinone;
(38) Ephedrone (sometimes used as another name for methcathinone)
2-(methylamino)-1-phenylpropan-1-one; OR 2-methylamino-1-phenylpropan-1-one;
(39) Ethcathinone, 2-ethylamino-1-phenyl-propan-1-one;
(40) Ethylethcathinone;
(41) Ethylmethcathinone;
(42) Ethylone 3,4-methylenedioxy-N-ethylcathinone; OR 3,4-methylenedioxyethylcathinone; OR 3,4-methylenedioxy-ethylcathinone; OR 3,4-methylenedioxyethcathinone;
(43) Eutylone beta-Keto-Ethylbenziodioxolylbutanamine;
(44) Fluorococaine;
(45) Fluoroethcathinone;
(46) Fluoroisocathinone;
(47) Fluoromethcathinone;
(48) HMMC 3-methoxymethcathinone;
(49) Isopentedrone;
(50) MaPPP, 4-MePPP, MPPP 4-methyl-alpha-pyrrolidinopropiophenone; OR 4-methyl-a-pyrrolidinopropiophenone; OR methylpyrrolidinopropiophenone; OR Methyl-pyrrolindinopropiophenone;
(51) MBP Methylbuphedrone;
(52) MBZP 1-methyl-4-benzylpiperazine;
(53) MDAI methylenedioxy-aminoindane; OR 5,6-methylenedioxy-2-aminoindane;
(54) MDAT 6,7-methylenedioxy-2-aminotetralin;
(55) MDDMA Dimethylone;
(56) MDMC Methylenedioxymethcathinone;
(57) MDPBP 3,4-methylenedioxy-alpha-pyrrolidinobutiophenone; OR 3,4-methylenedioxy-a-pyrrolidinobutiophenone;
(58) MDPPP 3,4-methylenedioxy-a-pyrrolidinopropiophenone; OR (RS)-1-(3,4-methylenedioxyphenyl)-2-(1-pyrrolidinyl)-1-propanone; OR 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone;
(59) MDPV, MDPK 3,4-methylenedioxypyrovalerone; OR methylenedioxypyrovalerone;
(60) MEC Methylethcathinone;
(61) Mephedrone, 4-MMC 4-methylmethcathinone; OR 4-methylephedrone; OR (RS)-2-methylamino-1-(4-methylphenyl)propan-1-one;
(62) Metamfepramone, N,N-DMMC N,N-dimethylcathinone;
(63) Methedrone, Bk-PMMA, PMMC para-methoxymethcathinone; OR 4-methoxymethcathinone; OR methoxyphedrine; OR (RS)-1-(4-methoxyphenyl)-2-(methylamino)propan-1-one;
(64) Methylmethcathinone;
(65) Methylone, bk-MDMA, MDMC 3,4-methylenedioxy-N-methylcathinone; OR 3,4-methylenedioxymethcathinone; OR 3,4-methylenedioxymethylcathinone;
(66) MOMC Methoxymethcathinone;
(67) MOPPP 4-methoxy-alpha-pyrrolidinopropiophenone; OR 4-methoxy-a-pyrrolidinopropiophenone;
(68) MPBP 4-methyl-alpha-pyrrolidinobutyrophenone; OR 4-methyl-a-pyrrolidinobutryophenone; OR 4-methyl-alpha-pyrrolidinobutiophenone; OR 4-methyl-a-pyrrolidinobutiophenone;
(69) NRG-1, Naphyrone naphthylpyrovalerone;
(70) NRG-2;
(71) Pentedrone a-methylamino-Valerophenone; OR 2-(methylamino)-1-phenyl-1-pentanone; OR 2-methylamino-1-phenyl-1-pentanone; and
(72) Pentylone beta-Keto-N-methylbenzodioxolylpentanamine; OR beta-keto-ethylbenzodioxolylpentanamine;
Subsection 1201.1(f)(2)(B) is amended to read as follows:
(B) AM-356 (methanandamide); (5Z,8Z,11Z,14Z)-N-[(1R)-2-hydroxy-1-methylethyl] icosa-5,8,11,14-tetraenamide; or arachidonyl-1'- hydroxy-2'-propylamide;
Subsection 1201.1(f)(2) is amended by adding four new paragraphs numbered (JJ) through (MM) as follows:
(JJ) THJ-2201 [1-(5-fluoropentyl)-1H-indazol-3-1yl](naphthalen-1-yl)methanone;
(KK) (N-(1-amino-3-methyl-1- oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide (“AB-CHMINACA”);
(LL) (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) (“AB-PINACA“); and
(MM) NM-2201, aka CBL-2201 naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate.
Subsection 1201.1 is amended by adding two new paragraphs (g) and (h) to read as follows:
(g) Substituted tryptamines. This includes any compound, unless specifically excepted, specifically named in this schedule, or listed under a different schedule, structurally derived from 2-(1H-indol-3-yl) ethanamine (i.e., tryptamine) by mono- or di-substitution of the amine nitrogen with alkyl or alkenyl groups or by inclusion of the amino nitrogen atom in a cyclic structure whether or not the compound is further substituted at the alpha position with an alkyl group or whether or not further substituted on the indole ring to any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy groups. Examples include the following:
(1) (4-AcO-DET) 3-(2-Diethylaminoethyl)-1H-indol-4-yl acetate;
(2) (4-AcO-DMT, OAcetylpsilocin) 4-acetoxy-N,N-dimethyltryptamine;
(3) (4-AcO-DPT) 4-acetoxy-N,N-dipropyltryptamine;
(4) (4-HO-DiPT) 4-Hydroxy-di-isopropyl-tryptamine; OR 3-[2- (diisopropylamino)ethyl]-1H-indol-4-ol; OR 4-Hydroxy- N,N-diisopropyltryptamine;
(5) (4-HO-MET) 4-hydroxy-N-methyl-N-ethyltryptamine;
(6) (4-HO-MiPT) 3-(2-[Isopropyl(methyl)amino]ethyl)-1H-indol-4-ol;
(7) (4-HO-MPMI) (R)-3-(N-methylpyrrolidin-2-ylmethyl)-4-hydoxyindole;
(8) (4-HO-MPT) 3-{2-[methyl(propyl)amino]ethyl}-1H-indol-4-ol; OR 4- hydroxy-N-methyl-N-propyltryptamine;
(9) (4-MeO-MiPT) 4-methoxy-N-methyl-N-isopropyltryptamine; OR 3-[2 (Isopropylmethylamino)ethyl]-4-methoxyindole;
(10) 4-methyl-aET 4-Methyl-α-ethyltryptamine; OR 1-ethyl-2-(4-methyl-1H- indol-3-yl)-ethylamine;
(11) (5-MeO-AMT) 1-(5-methoxy-1H-indol-3-yl)propan-2-amine;
(12) (5-MeO-DALT) N,N-diallyl-5-methoxytryptamine; OR N-allyl-N-[2-(5- methoxy-1H-indol-3-yl)ethyl]prop-2-en-1-amine;
(13) (5-MeO-DET) N,N-Dethyl-5-Methoxytryptamine;
(14) (5-MeO-DPT) N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-1- amine;
(15) (5-MeO-MiPT, Moxy, Moxie) N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine;
(16) (5-MeO-MPMI) (R)-3-(N-methylpyrrolidin-2-ylmethyl)-5-methoxyindole;
(17) (DPT) N,N-Dipropyltryptamine; OR Dipropyltryptamine; OR 3-[2-(dipropylamino)ethyl]indole;
(18) (Methyltryptamine, NMT) N-methyltryptamine; OR 2-(1H-Indol-3-yl)-N-methylethanamine; and
(19) (MiPT) N-isopropyl-N-methyltryptamine;
(h) Unclassified novel psychoactive substances:
(1) (2-AI, 2-aminoindane) 2,3-dihydro-1H-inden-2-amine;
(2) (2-FMA) 2-fluoromethamphetamine; OR (RS)-1-(2-fluorophenyl)-N-methylpropan-2-amine;
(3) (2-MeO-ketamine) methoxyketamine;
(4) (3-HO-PCE) 3-[1-(ethylamino) cyclohexyl]phenol;
(5) (3-HO-PCP) 3-hydroxyphencyclidine (3-MeO-PCE) 3-Methoxyeticyclidine;
(6) (3-MeO-PCP) 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine; OR 3-methoxyphencyclidine;
(7) (4-FMA) 4-fluoromethamphetamine; OR (RS)-1-(4-fluorophenyl)-N-methylpropan-2-amine;
(8) (4-MeO-PCP, methoxydine) 4-Methoxyphencyclidine; OR 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine;
(9) (5-IAI) 5-Iodo-2-aminoindane; OR 5-iodo-2,3-dihydro-1H-inden-2-amine;
(10) (5-ME) 5-methyl-ethylone;
(11) (BTCP) Benzothiophenylcyclohexylpiperidine;
(12) (DBP, DBZP) 1,4-Dibenzylpiperazine;
(13) (Ethyl-ketamine) 2-(2-chlorophenyl)-2-(ethylamino)cyclohexanone;
(14) (Fluoromethamphetamine);
(15) (Fluorophenylpiperazine; pFPP; 4-FPP; fluoperazine; flipiperazine) Para-fluorophenylpiperazine; OR 1-(4-fluorophenyl)piperazine;
(16) (Kratom) 7-hydroxymitragynine;
(17) (MCPP) 1-(3-Chlorophenyl)piperazine, OR Chlorophenylpiperazine, OR meta chlorophenylpiperazine; OR 1-(3-chlorophenyl)piperazine; OR 3-chlorophenylpiperazine;
(18) (Methiopropamine, MPA) 1-(thiophen-2-yl)-2-methylaminopropane;
(19) (Methoxetamine, MXE, 3 MeO-2-Oxo-PCE) (RS)2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone;
(20) (MPHP) Methyl-alpha-pyrrolidinohexiophenone; OR Methyl-pyrrolidino-hexanophenone;
(21) (O-desmethyltramadol, O-DT) 3-[2-(1-Amino-1-methylethyl)-1-hydroxycyclohexyl]phenol;
(22) (Phenazepam) 7-Bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one;
(23) (pMeOPP, MeOPP) 1-(4-Methoxyphenyl) piperazine;
(24) (pTFMPP) 1-[4-(trifluoromethylphenyl)] piperazine; and
(25) (TFMPP) 3-trifluoromethylphenylpiperazine; OR 1-[3-(trifluoromethyl)phenyl]piperazine; OR 1-(3-trifluoromethylphenyl) piperazine; OR 1-(3-trifluoromethylphenyl)piperazine; OR 1-(3-[trifluoromethylphenyl])piperazine.
Section 1204, SCHEDULE IV ENUMERATED, is amended as follows:
Subsection 1204.1(a) is amended by striking the word “and” at the end of paragraph (8), striking the period at the end of paragraph (9) and adding two new paragraphs (10) and (11) to read as follows:
(10) Suvorexant; and
(11) Tramadol.
